Finally, we identified seven novel potential target genes (UQCR11, UBE2N, ADD1, TLN1, IRAK3, LY96, and MAP3K1), which might be valid targets for therapeutic development for FH, and might be used as diagnostic biomarkers for FH patients and prognostic indicators for atherosclerosis using WBCs from FH patients; however, functional studies are needed to validate their proposed role in FH and atherosclerosis. The gene discussed is LY96; the disease is atherosclerosis.